---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-027754"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:10:25.171154+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q2 net loss $68.2M, revenues up 48%; RGX-314 BLA on track for 2024

## Summary
- Net loss $68.2M ($1.58/share) vs $57.6M ($1.36) in Q2 2021; revenues $32.6M up 48% YoY.
- Cash and marketable securities $682M (down from $849M Dec 2021); runway into 2025.
- RGX-314 (wet AMD/DR) on track for BLA in 2024; pivotal trials enrolling; AAVIATE Cohort 5 complete; ALTITUDE enrollment complete.
- RGX-121: intend to file BLA in 2024 via accelerated approval; pivotal CAMPSIITE trial active enrolling up to 10 patients.
- RGX-202 first patient dosing expected in first half 2023; NAV licensee Zolgensma Q2 sales $379M.

## SEC filing metadata
- accession: 0001564590-22-027754
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000156459022027754/0001564590-22-027754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000156459022027754/rgnx-8k_20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-027754
- JSON: https://secwatch.observer/filing/0001564590-22-027754.json
- Plain text: https://secwatch.observer/filing/0001564590-22-027754.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.